NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks
Three companies converged on orexin inside a fortnight, turning narcolepsy into one of the most contested races in neurology. Around it, a Duchenne filing took Priority Review and a $375 million raise the next day, a CHMP opinion slipped for manufacturing reasons rather than clinical ones, and the committee that twice refused a cerebral ALD drug recommended approving it.
programmes
milestones
financing
reversal
Three orexin agonists in two weeks, and narcolepsy turns into one of the most contested races in neurology
Lundbeck received FDA Fast Track designation for Lu AH69593, an investigational orexin-2 receptor agonist for narcolepsy. On its own a designation is procedural. Read across a fortnight and it is something else. In the past two weeks Alkermes reported long-term extension data showing its oral orexin-2 agonist alixorexton sustained wakefulness across narcolepsy types 1 and 2, Axsome had AXS-12 accepted by the FDA for cataplexy, and Lundbeck now takes Fast Track for a third mechanism-adjacent entrant. That is three companies converging on the same disorder inside fifteen days. The reason orexin has drawn this crowd is that it is one of the rare neurology targets with clean human validation: narcolepsy type 1 is caused by loss of orexin-producing neurons, so replacing the signal is mechanistic correction rather than symptom management, which is unusual in a field built largely on the latter. Two things now decide the race, and neither is efficacy in type 1, where all of these should work. The first is type 2, where the biology is murkier and the addressable population considerably larger. The second is safety at scale, because orexin agonism touches wake circuitry that is not confined to sleep-wake regulation. Watch which programme publishes clean long-term hepatic and cardiovascular data first. In a field this crowded, differentiation will be settled on tolerability, not on wakefulness.
Otsuka wins the first new ADHD mechanism in years, and it is still a scheduled stimulant
The FDA approved Otsuka’s SIMTRIYO (centanafadine) on 24 July for ADHD in adults and children aged 6 and over weighing at least 20kg, the first and only approved norepinephrine, dopamine and serotonin reuptake inhibitor. Four pivotal Phase 3 trials supported it, with symptom improvement on ADHD-RS-5 and AISRS visible as early as week 1, in a US population the CDC puts at roughly 22.5 million people. Read the label rather than the press release, though, because two details temper the framing. SIMTRIYO is classified as a CNS stimulant and cannot reach patients until the DEA schedules it, so this is a new mechanism inside the controlled-substance system rather than an escape from it. And it carries two boxed warnings: abuse, misuse and addiction, and higher rates of suicidal ideation and behaviours in treated children aged 6 to 12 than on placebo. That second warning is the one to watch, because it lands in the same paediatric population where families are actively seeking alternatives to existing stimulants. Set it beside NeuroSigma’s second-generation Monarch launch this week, the only FDA-cleared non-drug option in paediatric ADHD, and the week produced two answers to the same question from opposite directions. A positive Phase 3b in adults with comorbid anxiety, reported in June, widens the eventual label conversation.
Dyne takes Priority Review in exon 51 Duchenne with a January 2027 date, then raises $375 million the next day
The FDA accepted Dyne Therapeutics’ BLA for z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping, granting Priority Review with a PDUFA target action date of 21 January 2027. The submission seeks Accelerated Approval using dystrophin as a surrogate endpoint, supported by the registrational expansion cohort of the Phase 1/2 DELIVER trial, which met its primary endpoint with statistically significant dystrophin production on four-weekly dosing alongside functional improvement across multiple endpoints. The confirmatory Phase 3 FORZETTO trial is already enrolling, which matters in an indication where accelerated approvals have drawn criticism precisely when confirmatory work lagged. The commercial tell arrived a day later: Dyne priced an upsized $375 million offering. A regulatory milestone is the cheapest capital window a clinical-stage company gets, and this one was used inside 24 hours.
Scholar Rock’s CHMP opinion slips, and the reason is a contract manufacturer rather than the drug
Scholar Rock said the CHMP opinion on apitegromab in spinal muscular atrophy will take longer than guided. The cause sits outside the data package: the EMA is waiting on the FDA’s classification of an inspection at a third-party fill-finish facility, and resolution depends either on that reclassification or on Scholar Rock qualifying its second fill-finish site. This is the distinction worth holding onto when a date moves. A delay driven by chemistry, manufacturing and controls is not a delay driven by efficacy or safety, and the two carry very different risk. The dates that still matter are unchanged: a US PDUFA on 30 September 2026 and a company update at Q2 earnings on 6 August. Mark this as timing risk, not approvability risk, and note that supply-chain dependency is now a live regulatory variable rather than a background assumption.
CHMP recommends approval for a cerebral ALD drug it refused twice
The EMA’s CHMP recommended marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone) in male patients aged 2 to 12 with cerebral adrenoleukodystrophy and gadolinium-negative lesions, with European Commission approval expected by end-September. The same committee recommended refusal in February 2024 and upheld it on re-examination that May. Minoryx and Neuraxpharm returned with the completed 96-week Phase 2/3 NEXUS study plus compassionate-use evidence. For a childhood neurodegenerative disease whose only meaningful interventions have been stem cell transplant or gene therapy, an oral brain-penetrant option changes who is treatable at all, particularly away from transplant centres. The narrow label, a defined age band, gadolinium-negative lesions, exceptional circumstances, is the committee granting precisely what the evidence supports.
NeuroSense moves PrimeC toward a Canadian submission in ALS
NeuroSense Therapeutics advanced PrimeC toward a New Drug Submission to Health Canada for amyotrophic lateral sclerosis. Choosing Canada as a filing route ahead of larger markets is a recognised small-cap strategy in ALS, where regulatory flexibility and community pressure have produced unconventional pathways before. Worth watching as a route question rather than an evidence one.
Nuvation Bio reports updated Phase 2 data and expands its IDH1-mutant glioma programme
Nuvation Bio published positive updated Phase 2 results for safusidenib and expanded the programme. IDH-mutant glioma is one of the few brain tumour settings with a genuinely validated genetic target, and the arrival of a second credible entrant behind the established IDH inhibitor changes the competitive question from whether the mechanism works to how the assets differentiate on brain penetration, tolerability and line of therapy. Neuro-oncology rarely offers clean target validation, so contested ground here is a sign of a maturing space rather than a crowded one.
Lundbeck randomises its last patient in the Phase III DEEP OCEAN trial
Lundbeck completed randomisation in DEEP OCEAN, a large Phase III programme. Last-patient-in is a clock-starter rather than a result, and its analytical value is arithmetic: enrolment completion plus the primary endpoint interval plus data cleaning gives a defensible estimate of when topline arrives, usually more reliable than company guidance. Log it as a dated catalyst rather than news, and note that completing enrolment in a large CNS Phase III on schedule is itself a signal about investigator enthusiasm and site performance.
Actinogen reports proof-of-concept for Xanamem
Actinogen Medical released proof-of-concept trial results for Xanamem, its cortisol-modulating candidate. The cortisol hypothesis in cognitive disease has been persistently attractive and persistently difficult to convert into clinical benefit, so early positive signal deserves logging with the stage stated plainly. The value of proof-of-concept is that it justifies a larger study, not that it predicts one.
Three programmes complete enrolment and one clears an IND
Serina Therapeutics completed enrolment in its lead study, Helus Pharma finished enrolment in the Phase 3 APPROACH trial of HLP003 in an adjunctive setting, and Spryte Medical completed enrolment in its INSYTE trial. Separately, Consano Bio cleared an FDA investigational new drug application to expand a clinical programme. Enrolment completions are the least glamorous and most predictive items on any neuro board: they convert an open-ended readout window into a calculable one, and in CNS, where enrolment routinely runs late, finishing on time is a genuine differentiator.
Biotronik pairs an AI layer with new IP to sharpen a spinal cord stimulation play
Biotronik Neuro launched Embrace One, an AI capability for its Prospera spinal cord stimulation system that analyses more than 200 remote-monitoring data points per patient per day to flag patients who may need outreach. In an ASPN pilot the model surfaced 188 behavioural patterns across 175 patients, with patients responding to outreach in 80.9 percent of cases. The AI feature is not the story, the sequence is: the launch landed one week after Biotronik acquired spinal cord stimulation intellectual property from Soin Neuroscience. Two deliberate moves in seven days on one platform reads as a push into a market owned by Boston Scientific, Medtronic, Abbott and Nevro, and the chosen weapon is the tell. Rather than out-engineer the incumbents, Biotronik is using its remote-monitoring dataset as the moat.
A company formerly called StrokeDx clears a device that is not cleared to detect stroke
NeuraNova received 510(k) clearance for the STEDI Device, a bioimpedance spectroscopy system that assesses cerebral fluid volume asymmetry between hemispheres at the bedside, without imaging. Read the label carefully: it is cleared as an adjunct to standard clinical evaluation, not as a diagnostic. Then read the company’s former name. Bedside triage of suspected stroke without a scanner is one of the largest unmet needs in acute neurology, because the constraint on treatment is time to imaging and imaging is where the queue forms. Clearing a physiologic measurement is the entry ticket to that problem, not the solution. The rename, alongside two further platforms in development, signals a portable neuro-sensing portfolio rather than a single product.
The only non-drug paediatric ADHD device launches its second generation into a 1,500-family waitlist
NeuroSigma began US sales of the second-generation Monarch eTNS System, the only FDA-cleared non-drug treatment for paediatric ADHD, indicated as monotherapy for children aged 7 to 12 not currently taking ADHD medication. More than 1,500 patients, caregivers and providers are on the waitlist, which is a real demand signal for an alternative to stimulants. The question it does not answer is who pays, and a home-use neuromodulation device for a behavioural indication sits in exactly the category payers cover slowest. The more interesting strategic line is in the pipeline: the same platform holds Breakthrough Device Designation in drug-resistant epilepsy, an indication with clearer medical necessity and a far easier reimbursement argument.
Clearances, coverage and approvals across neurovascular and imaging
Rapid Medical received FDA clearance for DRIVEWIRE 35 and reported a first clinical use, adding to a neurovascular portfolio built around steerable access. Serenity Medical reported sustained performance data for its RIVER stent. Bracco Imaging secured approval in Mexico for Vueway (gadopiclenol), extending a contrast agent into a new market. Plus Therapeutics secured a regional coverage agreement, which is the item on this list that actually determines revenue, because in neuro devices and diagnostics reimbursement decides adoption far more reliably than clearance does. In South Korea, Neuronata-R retained its conditional approval, a reminder that conditional pathways carry ongoing evidentiary obligations rather than a settled outcome.
JCR gets its brain-penetrating Hunter syndrome therapy out of Japan for the first time
JCR Pharmaceuticals received marketing authorization in the United Arab Emirates for IZCARGO (pabinafusp alfa), its first authorization outside Japan since the 2021 launch there. The therapy crosses the blood-brain barrier via transferrin-receptor transcytosis using JCR’s J-Brain Cargo platform, targeting the central nervous system manifestations conventional enzyme replacement cannot reach. The read is the route rather than the revenue: JCR used its Japanese authorization as the basis for approval in a reliance market and handed commercialisation to a regional specialist, which for a disease affecting 2,000 to 3,000 people worldwide is the only economically rational way to reach patients outside the big three markets. The asset that matters most is the shuttle, not the enzyme.
Capital keeps moving into neuro, led by a $200 million private placement in migraine
The week’s largest financing was Mentari Therapeutics’ $200 million private placement for a migraine programme, a size that signals late-stage conviction rather than early-stage optimism and stands out in a field where CYP-independent oral options and the CGRP class have already set a high commercial bar. Beneath it, the pattern was steady rather than spectacular: Transcripta Bio raised $24 million to advance its platform, Magnendo secured an $18 million Series A, and Estrigenix Therapeutics closed a seed round. Read together, one large placement plus three small rounds is what a functioning but selective funding environment looks like, capital available for either de-risked late assets or cheap early options, with the middle squeezed.
Partnerships cluster around diagnostics, devices and cell therapy
Brainsway made a strategic investment in Radial Health, extending a neuromodulation company into care delivery rather than deeper into hardware. Tempest announced a development collaboration with Senlang, and Jupiter Neurosciences signed a definitive agreement. On the diagnostics side, ALZpath broadened its strategic agreement with Alamar Biosciences to advance clinical work on blood-based markers, while NanoSomiX and Beckman Coulter Diagnostics began collaborating on extracellular vesicle-based approaches. Lilac Biosciences and Soin Neuroscience published a clinical review together. The through-line across all of them is that none is a straightforward asset acquisition, they are capability partnerships, which is how a field behaves when the bottleneck is measurement and delivery rather than molecules.
Two Fast Track designations, and the one that matters is the third orexin entrant
Acadia Pharmaceuticals received FDA Fast Track designation, and Lundbeck received Fast Track for Lu AH69593 in narcolepsy. Fast Track confers more frequent agency interaction and rolling review eligibility rather than any evidentiary advantage, so treat the designation itself as procedural. The signal value sits in what it reveals about intent and priority: a company does not seek expedited status for an asset it plans to develop slowly. Lundbeck’s is the consequential one for the reasons set out in this week’s lead.
Two companies strengthen patent positions
Autonomix Medical secured a new US patent strengthening its position, and Clearmind Medicine expanded its global intellectual property portfolio. Patent news is the least reported and most durable item on a weekly board, because in neuro devices and psychedelics-adjacent chemistry the defensible position is frequently the method rather than the molecule. Neither item changes anything this quarter. Both change what a partner or acquirer is willing to pay later.
The research that will shape the next filings
Icahn School of Medicine at Mount Sinai published the structure of a brain protein and identified a potential drug target, which is the kind of structural work that precedes a decade of medicinal chemistry. The University of Virginia reported using focused ultrasound to deliver mRNA in glioblastoma, addressing the delivery problem that has defeated most brain tumour therapeutics rather than the payload problem. Mayo Clinic detailed how noninvasive brain stimulation could change epilepsy care. NMD Pharma published work identifying a neuromuscular mechanism. In Japan, researchers reported an Alzheimer’s finding, and blood-based biomarkers in Alzheimer’s disease continued their expansion into routine clinical use. None of this is investable this quarter. All of it determines what is filed in 2030.
This week is what happened. Catalyst and AccessWatch are what comes next.
The weekly Pulse closes the loop on the last seven days. The monthly beats open the next ninety.